Bicycle Therapeutics (NASDAQ:BCYC) Issues Quarterly Earnings Results

Bicycle Therapeutics (NASDAQ:BCYC) released its earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.25, FiscalAI reports. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. The firm had revenue of $34.06 million during the quarter, compared to the consensus estimate of $12.22 million.

Bicycle Therapeutics Stock Down 4.1%

Shares of Bicycle Therapeutics stock traded down $0.15 during trading on Friday, reaching $3.67. 267,674 shares of the stock were exchanged, compared to its average volume of 423,329. The stock’s fifty day moving average is $3.85 and its 200 day moving average is $4.60. The firm has a market cap of $256.52 million, a price-to-earnings ratio of -1.34 and a beta of 1.68. Bicycle Therapeutics has a 1 year low of $3.33 and a 1 year high of $8.48.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BCYC shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday. Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Zacks Research lowered shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Finally, Needham & Company LLC decreased their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $13.57.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.